Safety of guselkumab with and without prior TNF-α inhibitor treatment: pooled results across four studies in patients with psoriatic arthritis

<p><strong>Objective:</strong> Assess pooled safety results through the end of the Phase 2/3 studies of guselkumab (≤2 years) in tumor necrosis factor-α inhibitor (TNFi) -naïve and -experienced patients with psoriatic arthritis (PsA).</p> <p><strong>Methods:<...

Full description

Bibliographic Details
Main Authors: Rahman, P, Boehncke, W-H, Mease, PJ, Gottlieb, AB, McInnes, IB, Shawi, M, Wang, Y, Sheng, S, Kollmeier, AP, Theander, E, Yu, J, Leibowitz, E, Marrache, AM, Coates, LC
Format: Journal article
Language:English
Published: Journal of Rheumatology 2023
_version_ 1826310375746830336
author Rahman, P
Boehncke, W-H
Mease, PJ
Gottlieb, AB
McInnes, IB
Shawi, M
Wang, Y
Sheng, S
Kollmeier, AP
Theander, E
Yu, J
Leibowitz, E
Marrache, AM
Coates, LC
author_facet Rahman, P
Boehncke, W-H
Mease, PJ
Gottlieb, AB
McInnes, IB
Shawi, M
Wang, Y
Sheng, S
Kollmeier, AP
Theander, E
Yu, J
Leibowitz, E
Marrache, AM
Coates, LC
author_sort Rahman, P
collection OXFORD
description <p><strong>Objective:</strong> Assess pooled safety results through the end of the Phase 2/3 studies of guselkumab (≤2 years) in tumor necrosis factor-α inhibitor (TNFi) -naïve and -experienced patients with psoriatic arthritis (PsA).</p> <p><strong>Methods:</strong> Data were pooled from the Phase 2 and DISCOVER-1 (TNFi-naïve/experienced), DISCOVER-2 (TNFi-naïve), and COSMOS (TNFi-experienced) studies. Patients with active PsA were randomized to guselkumab 100 mg every 4 or 8 weeks (Q4W+Q8W=Combined Guselkumab) or placebo with crossover to guselkumab Q4W or Q8W at Week 24. Time-adjusted adverse event (AE) rates (events/100 patient-years [PY]) and clinical laboratory findings were assessed during the placebo-controlled period and through end of study.</p> <p><strong>Results:</strong> Of 1554 randomized patients (n=373 [guselkumab Q4W], 664 [guselkumab Q8W], and 517 [placebo]), 1138 (73.23%) were TNFi-naive and 416 (26.76%) were TNFi-experienced. Respective AE rates through Week 24 were 220.8/100PY (TNFi-naïve) and 251.6/100PY (TNFi-experienced) in the Combined Guselkumab group and 196.1/100PY (TNFi-naïve) and 303.0/100PY (TNFi-experienced) in the Placebo group. Among all guselkumab-treated patients (including those who crossed over from placebo), low AE rates were maintained during long-term evaluation in both TNFi-naïve (139.69/100PY) and TNFi-experienced (174.0/100PY) patients. Rates/100PY of AEs leading to treatment discontinuation, serious AEs, and other AEs of interest as well as occurrence of elevated hepatic transaminase levels and decreased neutrophil counts were consistent between placebo and guselkumab-treated patients through Week 24 treatment regardless of prior TNFi use and remained low through the end of the studies.</p> <p><strong>Conclusion:</strong> The safety profile of guselkumab in TNFi-experienced patients was consistent with that in TNFi-naïve patients, which remained favorable for up to 2 years.</p>
first_indexed 2024-03-07T07:49:34Z
format Journal article
id oxford-uuid:24b323e0-acd7-4c54-a2d7-1d6683d08b7a
institution University of Oxford
language English
last_indexed 2024-03-07T07:49:34Z
publishDate 2023
publisher Journal of Rheumatology
record_format dspace
spelling oxford-uuid:24b323e0-acd7-4c54-a2d7-1d6683d08b7a2023-07-12T09:06:06ZSafety of guselkumab with and without prior TNF-α inhibitor treatment: pooled results across four studies in patients with psoriatic arthritisJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:24b323e0-acd7-4c54-a2d7-1d6683d08b7aEnglishSymplectic ElementsJournal of Rheumatology2023Rahman, PBoehncke, W-HMease, PJGottlieb, ABMcInnes, IBShawi, MWang, YSheng, SKollmeier, APTheander, EYu, JLeibowitz, EMarrache, AMCoates, LC<p><strong>Objective:</strong> Assess pooled safety results through the end of the Phase 2/3 studies of guselkumab (≤2 years) in tumor necrosis factor-α inhibitor (TNFi) -naïve and -experienced patients with psoriatic arthritis (PsA).</p> <p><strong>Methods:</strong> Data were pooled from the Phase 2 and DISCOVER-1 (TNFi-naïve/experienced), DISCOVER-2 (TNFi-naïve), and COSMOS (TNFi-experienced) studies. Patients with active PsA were randomized to guselkumab 100 mg every 4 or 8 weeks (Q4W+Q8W=Combined Guselkumab) or placebo with crossover to guselkumab Q4W or Q8W at Week 24. Time-adjusted adverse event (AE) rates (events/100 patient-years [PY]) and clinical laboratory findings were assessed during the placebo-controlled period and through end of study.</p> <p><strong>Results:</strong> Of 1554 randomized patients (n=373 [guselkumab Q4W], 664 [guselkumab Q8W], and 517 [placebo]), 1138 (73.23%) were TNFi-naive and 416 (26.76%) were TNFi-experienced. Respective AE rates through Week 24 were 220.8/100PY (TNFi-naïve) and 251.6/100PY (TNFi-experienced) in the Combined Guselkumab group and 196.1/100PY (TNFi-naïve) and 303.0/100PY (TNFi-experienced) in the Placebo group. Among all guselkumab-treated patients (including those who crossed over from placebo), low AE rates were maintained during long-term evaluation in both TNFi-naïve (139.69/100PY) and TNFi-experienced (174.0/100PY) patients. Rates/100PY of AEs leading to treatment discontinuation, serious AEs, and other AEs of interest as well as occurrence of elevated hepatic transaminase levels and decreased neutrophil counts were consistent between placebo and guselkumab-treated patients through Week 24 treatment regardless of prior TNFi use and remained low through the end of the studies.</p> <p><strong>Conclusion:</strong> The safety profile of guselkumab in TNFi-experienced patients was consistent with that in TNFi-naïve patients, which remained favorable for up to 2 years.</p>
spellingShingle Rahman, P
Boehncke, W-H
Mease, PJ
Gottlieb, AB
McInnes, IB
Shawi, M
Wang, Y
Sheng, S
Kollmeier, AP
Theander, E
Yu, J
Leibowitz, E
Marrache, AM
Coates, LC
Safety of guselkumab with and without prior TNF-α inhibitor treatment: pooled results across four studies in patients with psoriatic arthritis
title Safety of guselkumab with and without prior TNF-α inhibitor treatment: pooled results across four studies in patients with psoriatic arthritis
title_full Safety of guselkumab with and without prior TNF-α inhibitor treatment: pooled results across four studies in patients with psoriatic arthritis
title_fullStr Safety of guselkumab with and without prior TNF-α inhibitor treatment: pooled results across four studies in patients with psoriatic arthritis
title_full_unstemmed Safety of guselkumab with and without prior TNF-α inhibitor treatment: pooled results across four studies in patients with psoriatic arthritis
title_short Safety of guselkumab with and without prior TNF-α inhibitor treatment: pooled results across four studies in patients with psoriatic arthritis
title_sort safety of guselkumab with and without prior tnf α inhibitor treatment pooled results across four studies in patients with psoriatic arthritis
work_keys_str_mv AT rahmanp safetyofguselkumabwithandwithoutpriortnfainhibitortreatmentpooledresultsacrossfourstudiesinpatientswithpsoriaticarthritis
AT boehnckewh safetyofguselkumabwithandwithoutpriortnfainhibitortreatmentpooledresultsacrossfourstudiesinpatientswithpsoriaticarthritis
AT measepj safetyofguselkumabwithandwithoutpriortnfainhibitortreatmentpooledresultsacrossfourstudiesinpatientswithpsoriaticarthritis
AT gottliebab safetyofguselkumabwithandwithoutpriortnfainhibitortreatmentpooledresultsacrossfourstudiesinpatientswithpsoriaticarthritis
AT mcinnesib safetyofguselkumabwithandwithoutpriortnfainhibitortreatmentpooledresultsacrossfourstudiesinpatientswithpsoriaticarthritis
AT shawim safetyofguselkumabwithandwithoutpriortnfainhibitortreatmentpooledresultsacrossfourstudiesinpatientswithpsoriaticarthritis
AT wangy safetyofguselkumabwithandwithoutpriortnfainhibitortreatmentpooledresultsacrossfourstudiesinpatientswithpsoriaticarthritis
AT shengs safetyofguselkumabwithandwithoutpriortnfainhibitortreatmentpooledresultsacrossfourstudiesinpatientswithpsoriaticarthritis
AT kollmeierap safetyofguselkumabwithandwithoutpriortnfainhibitortreatmentpooledresultsacrossfourstudiesinpatientswithpsoriaticarthritis
AT theandere safetyofguselkumabwithandwithoutpriortnfainhibitortreatmentpooledresultsacrossfourstudiesinpatientswithpsoriaticarthritis
AT yuj safetyofguselkumabwithandwithoutpriortnfainhibitortreatmentpooledresultsacrossfourstudiesinpatientswithpsoriaticarthritis
AT leibowitze safetyofguselkumabwithandwithoutpriortnfainhibitortreatmentpooledresultsacrossfourstudiesinpatientswithpsoriaticarthritis
AT marracheam safetyofguselkumabwithandwithoutpriortnfainhibitortreatmentpooledresultsacrossfourstudiesinpatientswithpsoriaticarthritis
AT coateslc safetyofguselkumabwithandwithoutpriortnfainhibitortreatmentpooledresultsacrossfourstudiesinpatientswithpsoriaticarthritis